Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clinton Yam

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Nature|May 13, 2026
Ecotypes of triple-negative breast cancer in response to chemotherapyYun Yan, Yiyun Lin, Tapsi Kumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to ChemotherapyToshiaki Iwase, Evan N Cohen, Hui Gao, et al.
NPJ Precision Oncology|November 18, 2024
Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancerXiaoping Wang, Li Zhao, Xingzhi Song, et al.
BMC Cancer|August 15, 2024
Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNAJennifer H Chen, Sridevi Addanki, Dhruvajyoti Roy, et al.
Breast Cancer Research and Treatment|June 1, 2026
Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trialKamaria L Lee, Clinton Yam, Li Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2017
A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid TumorsClinton Yam, Xiaowei Xu, Michael A Davies, et al.
Biorxiv : the Preprint Server for Biology|December 9, 2024
An annotated biobank of triple negative breast cancer patient-derived xenografts featuring treatment-naïve and longitudinal samples throughout neoadjuvant chemotherapyAmanda L Rinkenbaugh, Yuan Qi, Shirong Cai, et al.
Nature Communications|December 31, 2024
NOS inhibition sensitizes metaplastic breast cancer to PI3K inhibition and taxane therapy via c-JUN repressionTejaswini Reddy, Akshjot Puri, Liliana Guzman-Rojas, et al.
Cancer Research|August 13, 2025
An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples During Neoadjuvant ChemotherapyAmanda L Rinkenbaugh, Yuan Qi, Shirong Cai, et al.
Breast Cancer Research and Treatment|April 15, 2023
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancerClinton Yam, Elizabeth A Mittendorf, Haven R Garber, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Nature|May 13, 2026
Ecotypes of triple-negative breast cancer in response to chemotherapyYun Yan, Yiyun Lin, Tapsi Kumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to ChemotherapyToshiaki Iwase, Evan N Cohen, Hui Gao, et al.
NPJ Precision Oncology|November 18, 2024
Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancerXiaoping Wang, Li Zhao, Xingzhi Song, et al.
BMC Cancer|August 15, 2024
Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNAJennifer H Chen, Sridevi Addanki, Dhruvajyoti Roy, et al.
Breast Cancer Research and Treatment|June 1, 2026
Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trialKamaria L Lee, Clinton Yam, Li Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2017
A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid TumorsClinton Yam, Xiaowei Xu, Michael A Davies, et al.
Biorxiv : the Preprint Server for Biology|December 9, 2024
An annotated biobank of triple negative breast cancer patient-derived xenografts featuring treatment-naïve and longitudinal samples throughout neoadjuvant chemotherapyAmanda L Rinkenbaugh, Yuan Qi, Shirong Cai, et al.
Nature Communications|December 31, 2024
NOS inhibition sensitizes metaplastic breast cancer to PI3K inhibition and taxane therapy via c-JUN repressionTejaswini Reddy, Akshjot Puri, Liliana Guzman-Rojas, et al.
Cancer Research|August 13, 2025
An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples During Neoadjuvant ChemotherapyAmanda L Rinkenbaugh, Yuan Qi, Shirong Cai, et al.
Breast Cancer Research and Treatment|April 15, 2023
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancerClinton Yam, Elizabeth A Mittendorf, Haven R Garber, et al.
Pageof 7